Use of a fixed combination of ramipril with rosuvastatin in the management of lipitension: an observational study

Česká verzia

Authors: Štefan Tóth ^1,2,3; Dominika Zábavská ⁴
Authors place of work: SLOVACRIN, LF UPJŠ v Košiciach ¹; MEDIPARK, LF UPJŠ v Košiciach ²; Kardiologická ambulancia, Kardiocomp s. r. o., Košice ³; Katedra obchodného a hospodárskeho práva, Právnická fakulta, UPJŠ v Košisicach ⁴
Published in the journal: AtheroRev 2023; 8(3): 165-171
Category: Clinical Studies

Summary

Introduction: Cardiovascular diseases (CVD) are the most common cause of morbidity as well as mortality. The name lipertension is a common designation for one of the most important risk factors for CVD, namely hypertension and dyslipidemia. The aim of this study was to investigate the achievement of target lipid and blood pressure values in patients with fixed combination of ramipril and rosuvastatin (Rosu+Ram), patients’ adherence to therapy, as well as the prevalence of adverse effects of statin therapy. Methods: In this observational study, we enrolled a total of 54 patients with stage I hypertension with fixed combination Rosu+Ram as standard controls in the cardiology outpatient clinic of Cardiocomp Ltd and 80 patients who had ACEi and statin therapy in a form other than polypill as controls. We compared the patients’ baseline lipid profile as well as the lipid profile after at least 3 months of antihypertensive and hypolipemic therapy. We determined the success of achieving target blood pressure values (% of readings in the target range, last week before follow-up, at least 2 readings per day), and patients also completed a questionnaire to determine adherence to therapy as well as subjective negative effects of statins. Results: In this study, we found that on average 70% of blood pressure values in Rosu+Ram patients were in the therapeutic range, while in the control group it was 57%. Mean blood pressure values were 127.4 ± 10.8 mm Hg vs 133 ± 9.7 mm Hg in Rosu+Ram (p = 0.021). Target LDL-cholesterol (LDL-C) values were achieved by 87% of the Rosu+Ram group (N = 47) and 52% of the control group (N = 42); mean LDL-C values were 2.1 ± 1.1 mmol/L in Rosu+Ram vs 2.6 ± 1.2 mmol/L in the control group (p = 0.02). Adherence to therapy was significantly higher in the Rosu+Ram group vs the statin-control group (92% vs 65%), and the prevalence of adverse events was significantly lower, as was their severity, in the Rosu+Ram group vs the control group. Conclusion: Based on the results of this observational study, we hypothesize that the fixed combination of Rosu+Ram improves the achievement of target lipid as well as blood pressure values, improves adherence and reduces the prevalence of subjective adverse effects of statin therapy.

Keywords:

achieving target values – hypercholesterolemia – hypertension – hypertension – lipertension – ramipril – rosuvastatin

Zdroje

Vardas P, Townsend N, Torbica A et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022; 43(8): 716–799. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab892>.
Tóth Š, Pella D. Ako sme na tom s dosahovaním cieľových hladín LDL cholesterolu na Slovensku u vysoko-rizikovej populácie? AtheroRev 2022; 7(2): 110–115.
Howard JP, Wood FA, Finegold JA et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol 2021; 78(12): 1210–1222. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2021.07.022>.
Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39(33): 3021–3104. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehy339>. Erratum in Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2019; 40(5): 475. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehy686>.
Thoenes M, Bramlage P, Zhong S et al. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract 2012; 2012: 925046. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/925046>.
Čaprnda M, Kromka P, Tomášik J et al. Lipitenzia: nové možnosti kombinovanej liečby. AtheroRev 2023; 8(1): 25–31.
Tóth Š, Šajty M, Pekárová T et al. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. J Basic Clin Physiol Pharmacol 2017; 28(4): 327–336. Dostupné z DOI: <http://dx.doi.org/10.1515/jbcpp-2016–0149>.
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326(7404): 1419. Dostupné z DOI: <http://dx.doi.oeg/10.1136/bmj.326.7404.1419>. Erratum in BMJ 2003; 327(7415): 586. BMJ 2006; 60(9): 823.
Visseren FL, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227–3337. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab484>.
Mancia G, Facchetti R, Bombelli M et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45(6): 1072–1077. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000165672.69176.ed>.
Thomas F, Bean K, Guize L et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002; 23(7): 528–535. Dostupné z DOI: <http://dx.doi.org/10.1053/euhj.2001.2888>.
Wohlfahrt P, Krajčoviechová A, Bruthans J et al. Hypertension and hypercholesterolemia in the Czech population. Vnitr Lek 2016; 62(11): 863–867.
Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. CARE Investigators. Clin Ther 1993; 15(5): 810–818.
Yusuf S, Sleight P, Pogue J et al. [Heart Outcomes Prevention Evaluation Study Investigators]. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3): 145–153. Dostupné z DOI: <http://dx.doi.oeg/10.1056/NEJM200001203420301>.
[Investigators HOPEHS Heart Outcomes Prevention Evaluation Study Investigators]. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253–259. Erratum in Lancet 2000; 356(9232): 860.
[Gisen Group]. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349(9069): 1857–1863.
Effect of ramipril on mortality and morbidity of survivors of acute myo-cardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875): 821–828.
Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allo- cated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349(9064): 1493–1497. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(97)04442–5>.
Kotseva K, Wood D, De Backer G et al. [EUROASPIRE Study Group]. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–940. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60330–5>.
Kotseva K, Wood D, De Bacquer D et al. [EUROASPIRE Investigators]. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23(6): 636–648. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487315569401>.
De Backer G, Jankowski P, Kotseva, K et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285: 135–146. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.03.014>.
Mert GÖ, Başaran Ö, Mert KU et al. The reasons of poor lipid target attainment for secondary prevention in real life practice: Results from EPHESUS. International Journal of Clinical Practice 2019; 73(9): 1–9. Dostupné z DOI: <http://dx.doi.org/10.1111/ijcp.13358>.
Gitt AK, Drexel H, Feely J et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012; 19(2): 221–230. Dostupné z DOI: <http://dx.doi.org/10.1177/1741826711400545>.
März W, Dippel FW, Theobald K et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis 2018; 268: 99–107. Dostupné z DOI: <http://dx.doi.lorg/10.1016/j.atherosclerosis.2017.11.020>.
Ray KK, Molemans B, Schoonen WM et al. [DA VINCI study]. EU-Wi de Cross-Section al Observation al Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 2021; 28(11): 1279–1289. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/zwaa047>.
Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373(9670):1175–1182. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(09)60447–5>.
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326(7404): 1423. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.326.7404.1423>.
Vrablik M, Seifert B Parkhomenko A et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021; 334: 66–75. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2021.08.035>.
Sonel AF, Good CB, Mulgund J et al. Racial variations in treatment and outcomes of black and white patients with high-risk non–ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines?). Circulation 2005; 111(10): 1225–1232. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000157732.03358.64>.
Tóth Š. Praktický sprievodca k hypolipemickej terapii. Vysokoškolský učebný text. Univerzita Pavla Jozefa Šafárika v Košiciach – Vydavateľstvo ŠafárikPress: Košice 2022. ISBN 978–80–574–0086–8. Dostupné z WWW: <https://unibook.upjs.sk/img/cms/2022/lf/prakticky-sprievodca-hypolipemickej-terapii.pdf>.
Hasani-Ranjbar S, Ejtahed HS. Statins alone or polypill for primary prevention of cardiovascular diseases. J Diabetes Metab Disord 2016; 15: 55. Dostupné z DOI: <http://dx.doi.org/10.1186/s40200–016–0280–4>.
Mostaza, J.M., Suárez-Fernández, C., Cosín-Sales, J et al. [VULCANO investigators]. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial. BMC Cardiovasc Disord 2022; 22(1): 560. Dostupné z DOI: <http://dx.doi.org/10.1186/s12872–022–03013-w>.
Tóth Š. Praktický sprievodca k hypolipemickej terapii. ŠafárikPress: Košice 2022. ISBN 978-80-574-0086-8 (e-publikácia).